Burden of Herpes Zoster in the Japanese Population with Immunocompromised/Chronic Disease Conditions: Results from a Cohort Study Claims Database from 2005-2014
Burden of Herpes Zoster in the Japanese Population with Immunocompromised/Chronic Disease Conditions: Results from a Cohort Study Claims Database from 2005-2014
复制标题
DOI：
10.1007/s13555-018-0268-8
复制
发表时间：
2019-03-01
影响因子：
3.4
通讯作者：
Holl, Katsiaryna
中科院分区：
文献类型：
--
作者：
Imafuku, Shinichi;Matsuki, Taizo;Holl, Katsiaryna
简介本研究的目的是描述带状疱疹 (HZ) 在日本普通成年人口或患有免疫功能低下 (IC) 疾病或慢性疾病的患者中的疾病负担和费用。方法使用日本医疗数据中心索赔数据库 2005 年 1 月至 2014 年 12 月的记录对 18-74 岁的个体进行回顾性队列研究。 28 种 IC 病症和慢性疾病通过诊断代码和/或程序/治疗进行定义。已确定带状疱疹及其相关并发症。估计了发病率（IR）、带状疱疹相关并发症的发生频率、医疗资源利用率（HRU）和直接医疗费用。 HRU 和费用是根据 2012 年 4 月至 2014 年 1 月发生的带状疱疹病例子队列进行估计的。结果在 2,778,476 名成年人的总队列中，带状疱疹的总体 IR 为 4.92/1000 人年 (PY) [95% 置信区间 (CI)：4.86-4.98]，并随着年龄的增长而增加。 IC 队列（51,818 名受试者）的 IR 为 8.87/1000 PY（95% CI：8.29-9.48），范围从银屑病的 5.55/1000 PY（95% CI：4.26-7.09）到 151.68/1000 PY（95% CI： 111.45-201.71) 造血干细胞移植受者；大多数 IR 范围为 6-10/1000 PY。患有慢性疾病的个体的 IR 也相对较高，在 5.40-12.90/1000 PY 范围内。带状疱疹后神经痛的发生率在整个队列中为 4.01% (95% CI: 3.72-4.33)，在 IC 队列中为 11.73% (95% CI: 9.01-14.93)。平均[标准差(SD)]门诊就诊次数分别为3.4(4.9)和5.0(5.7)，带状疱疹患者住院比例分别为2.20%和6.70%。每次 HZ 发作的平均 (SD) 直接医疗费用在总体和 IC 队列中分别为 34,664 日元 (54,433 日元) 和 55,201 日元 (92,642 日元)。结论我们的研究中记录的患有 IC 疾病和慢性疾病的日本人中 HZ 负担增加，强调了在患有这些疾病的人中预防 HZ 的必要性。资助 GlaxoSmithKline Biologicals SA。
IntroductionThe aim of this study is to describe the disease burden and costs of herpes zoster (HZ) in the general adult Japanese population or patients with immunocompromised (IC) conditions or chronic disorders.MethodsA retrospective cohort study of individuals aged 18-74years was conducted using January 2005 to December 2014 records from the Japan Medical Data Center claims database. Twenty-eight IC conditions and chronic disorders were defined by diagnosis codes and/or procedures/treatments. HZ and its related complications were identified. Incidence rates (IR), frequency of HZ-related complications, healthcare resource utilization (HRU), and direct medical costs were estimated. HRU and costs were estimated on a subcohort of HZ cases occurring April 2012-January 2014.ResultsThe overall IR of HZ in the total cohort of 2,778,476 adults was 4.92/1000 person-years (PY) [95% confidence interval (CI): 4.86-4.98] and increased with age. The IR in the IC cohort (51,818 subjects) was 8.87/1000 PY (95% CI: 8.29-9.48), ranging from 5.55/1000 PY (95% CI: 4.26-7.09) in psoriasis to 151.68/1000 PY (95% CI: 111.45-201.71) in hematopoietic stem cell transplant recipients; most IRs were in the range 6-10/1000 PY. The IRs in individuals with chronic disorders were also relatively high, in the range 5.40-12.90/1000 PY. The frequency of postherpetic neuralgia was 4.01% (95% CI: 3.72-4.33) in the total cohort and 11.73% (95% CI: 9.01-14.93) in the IC cohort. The mean [standard deviation (SD)] number of outpatient visits was 3.4 (4.9) and 5.0 (5.7), respectively, and the proportion of HZ patients hospitalized was 2.20% and 6.70%, respectively. The mean (SD) direct medical cost per HZ episode was yen34,664 (yen54,433) and yen55,201 (yen92,642) in the total and IC cohort, respectively.ConclusionsThe elevated burden of HZ in Japanese individuals harboring IC conditions and chronic disorders documented in our study underlines the need for prevention of HZ in people with these conditions.FundingGlaxoSmithKline Biologicals SA.